S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

• Pankit Vachhani,
• Andrew Perkins,
• John Mascarenhas,
• Haifa Kathrin Al-Ali,
• Jean-Jacques Kiladjian,
• Sonia Cerquozzi,
• Jaroslaw Dybko,
• Regina Garcia Delgado,
• Jesus Hernández Rivas,
• Holger Hebart,
• Zhuying Huang,
• Cecile Krejsa,
• Hope Qamoos,
• Jesse Mcgreivy,
• Wayne P. Rothbaum,
• Srdan Verstovsek,
• Alessandro Vannucchi

Affiliations

Pankit Vachhani

1 University of Alabama at Birmingham, Birmingham, United States

Andrew Perkins

2 The Alfred Hospital and Monash University, Melbourne, Australia

John Mascarenhas

3 Icahn School of Medicine at Mount Sinai, New York, United States

Haifa Kathrin Al-Ali

4 University Hospital of Halle, Halle, Germany

Jean-Jacques Kiladjian

5 Hopital Saint-Louis, Paris, France

Sonia Cerquozzi

6 Tom Baker Cancer Center, Calgary, Canada

Jaroslaw Dybko

7 Lower Silesian Center of Oncology, Pulmonology and Hematology, Wroclaw, Poland

Regina Garcia Delgado

8 Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain

Jesus Hernández Rivas

9 Universidad de Salamanca, Hospital Universitario de Salamanca, Salamanca, Spain

Holger Hebart

10 Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany

Zhuying Huang

11 Kartos Therapeutics, Inc., Redwood City, CA, United States

Cecile Krejsa

11 Kartos Therapeutics, Inc., Redwood City, CA, United States

Hope Qamoos

11 Kartos Therapeutics, Inc., Redwood City, CA, United States

Jesse Mcgreivy

11 Kartos Therapeutics, Inc., Redwood City, CA, United States

Wayne P. Rothbaum

11 Kartos Therapeutics, Inc., Redwood City, CA, United States

Srdan Verstovsek

12 The University of Texas MD Anderson Cancer Center, Houston, United States

Alessandro Vannucchi

13 University of Florence, Florence, Italy